OmniAb (OABI) Projected to Announce Earnings on Thursday

OmniAb (NASDAQ:OABI) is expected to be posting its Q2 2026 results after the market closes on Thursday, August 6th. Analysts expect OmniAb to post earnings of ($0.11) per share and revenue of $4.6930 million for the quarter. Interested persons can check the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Thursday, August 6, 2026 at 4:30 PM ET.

OmniAb (NASDAQ:OABI) last issued its earnings results on Thursday, May 7th. The company reported ($0.06) EPS for the quarter, topping the consensus estimate of ($0.10) by $0.04. The company had revenue of $14.43 million for the quarter, compared to analyst estimates of $5.60 million. OmniAb had a negative net margin of 187.59% and a negative return on equity of 20.31%. On average, analysts expect OmniAb to post $-0 EPS for the current fiscal year and $-0 EPS for the next fiscal year.

OmniAb Price Performance

OABI opened at $1.95 on Thursday. The stock has a market cap of $282.32 million, a P/E ratio of -4.24 and a beta of 0.43. OmniAb has a 1-year low of $1.30 and a 1-year high of $2.79. The stock’s 50 day simple moving average is $2.33 and its 200 day simple moving average is $1.95.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings raised shares of OmniAb from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, July 21st. Two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, OmniAb presently has an average rating of “Hold” and an average price target of $3.00.

Institutional Trading of OmniAb

Several hedge funds have recently bought and sold shares of OABI. AQR Capital Management LLC acquired a new position in OmniAb during the 1st quarter valued at about $25,000. Osaic Holdings Inc. boosted its position in shares of OmniAb by 214.4% in the second quarter. Osaic Holdings Inc. now owns 14,247 shares of the company’s stock worth $25,000 after buying an additional 9,716 shares during the period. BNP Paribas Financial Markets grew its stake in OmniAb by 92.5% during the 3rd quarter. BNP Paribas Financial Markets now owns 21,721 shares of the company’s stock valued at $35,000 after acquiring an additional 10,438 shares in the last quarter. Cerity Partners LLC lifted its position in OmniAb by 111.5% in the 2nd quarter. Cerity Partners LLC now owns 22,612 shares of the company’s stock worth $39,000 after buying an additional 11,919 shares in the last quarter. Finally, The Manufacturers Life Insurance Company acquired a new position in OmniAb in the 4th quarter worth about $54,000. 72.08% of the stock is currently owned by institutional investors.

About OmniAb

OmniAb, Inc (NASDAQ: OABI) operates as a biotechnology company specializing in the discovery and development of therapeutic antibodies. The company’s integrated antibody discovery platform combines proprietary transgenic animal models, in vitro screening, and in silico engineering to accelerate lead identification and optimization. OmniAb offers both fee-for-service collaborations and license agreements, enabling biopharmaceutical partners to leverage its suite of technologies for programs spanning oncology, immunology, and other therapeutic areas.

Founded in 2016 and headquartered in Seattle, Washington, OmniAb went public in May 2021.